EC
AURA icon

EntryPoint Capital’s Aura Biosciences AURA Stock Holding History

EntryPoint Capital’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$176K Hold
26,300
– – 0.05% 662
2025
Q4 		$143K Buy
+26,300
New +$156K 0.06% 594
2024
Q3 		– Sell
-3,571
Closed -$27K – 642
2024
Q2 		$27K Sell
3,571
-4,683
-57% -$34.3K 0.04% 677
2024
Q1 		$64.8K Sell
8,254
-14,262
-63% -$118K 0.06% 631
2023
Q4 		$199K Buy
+22,516
New +$191K 0.19% 98

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EntryPoint Capital's AURA Position: Q1 2026 in Review

EntryPoint Capital held its Aura Biosciences (AURA) position steady in Q1 2026 at 26,300 shares worth $176K. The position accounts for 0.05% of the portfolio, ranked #662.

EntryPoint Capital first reported a position in AURA in Q4 2023 and has held it in 5 quarters since. The position peaked at $199K in Q4 2023. 126 funds tracked by Wall St. Rank hold AURA as of Q1 2026.

  • EntryPoint Capital held 26,300 shares of Aura Biosciences worth $176K as of Q1 2026.
  • EntryPoint Capital left its Aura Biosciences share count unchanged in Q1 2026.
  • Aura Biosciences made up 0.05% of EntryPoint Capital's portfolio in Q1 2026, its #662 holding.
  • EntryPoint Capital first reported a position in Aura Biosciences in Q4 2023 and has held it in 5 quarters since.
  • EntryPoint Capital's Aura Biosciences position peaked at $199K in Q4 2023.
  • 126 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.